MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) has announced results from a preclinical study of its investigational cannabinoid Supera-CBD™. Supera-CBD eased heat-related pain due to inflammation quickly…
Cognition Therapeutics (Nasdaq: CGTX) will present findings from studies of CT1812 for the treatment of adults with early, mild and moderate Alzheimer’s disease at the…
Viking Therapeutics (Nasdaq: VKTX) has presented new data from a Phase 1 clinical trial of its GLP-1 drug VK2735 at ObesityWeek 2023. In the study,…
October 19, 2023
Sage Therapeutics Granted Orphan Drug Designation for Huntington’s Disease Treatment
Biopharmaceutical company, Sage Therapeutics (Nasdaq: SAGE) has been granted Orphan Drug Designation for SAGE-718 for the treatment of Huntington’s disease (HD) by the FDA. SAGE-718…
October 19, 2023
Annovis Bio Alzheimer’s Study “Powered For Potential Success”
Annovis Bio (Nasdaq: ANVS) has announced its Phase 2/3 study evaluating a treatment for Alzheimer’s disease (AD) is sufficiently powered to continue as originally planned…
Incyte Corporation (Nasdaq: INCY) has announced new results of a long-term extension from its pivotal Phase 3 program assessing Opzelura® (ruxolitinib) cream in patients with…
Biopharmaceutical company, Nkarta (Nasdaq: NKTX) has received FDA clearance for its Investigational New Drug (IND) application to evaluate NKX019 for the treatment of lupus nephritis…
October 12, 2023
Immunic Reports Positive Data from Multiple Sclerosis Trial
Immunic, Inc. (Nasdaq: IMUX) has reported positive interim data from its Phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis (PMS). The…
October 11, 2023
Alkermes Takes on Narcolepsy at World Sleep Congress
Alkermes plc (Nasdaq: ALKS) is set to present new data related to ALKS 2680, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development…
October 10, 2023
Numinus Launches Psychedelic Program for Mental Distress
Numinus Wellness (OTC: NUMIF) has launched an innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. The…
October 09, 2023
A Billion Dollar Solution for Inflammatory Bowel Disease
Sanofi (Nasdaq: SNY) and Teva Pharmaceuticals (NYSE: TEVA) will collaborate to deliver a treatment for inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative…
October 09, 2023
Reviva’s Schizophrenia Therapeutic On Track to Change Lives
Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) has evaluated the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia. More than…